HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Co-delivery of GOLPH3 siRNA and gefitinib by cationic lipid-PLGA nanoparticles improves EGFR-targeted therapy for glioma.

Abstract
Glioblastoma is one of the most aggressive types of brain tumor. Epidermal growth factor receptors (EGFRs) are overexpressed in glioma, and EGFR amplifications and mutations lead to rapid proliferation and invasion. EGFR-targeted therapy might be an effective treatment for glioma. Gefitinib (Ge) is an EGFR tyrosine kinase inhibitor (TKI), and Golgi phosphoprotein 3 (GOLPH3) expression is associated with worse glioma prognosis. Downregulation of GOLPH3 could promote EGFR degradation. Here, an angiopep-2 (A2)-modified cationic lipid-poly (lactic-co-glycolic acid) (PLGA) nanoparticle (A2-N) was developed that can release Ge and GOLPH3 siRNA (siGOLPH3) upon entering glioma cells and therefore acts as a combinatorial anti-tumor therapy. The in vitro and in vivo studies proved that A2-N/Ge/siGOLPH3 successfully crossed the blood-brain barrier (BBB) and targeted glioma. Released siGOLPH3 effectively silenced GOLPH3 mRNA expression and further promoted EGFR and p-EGFR degradation. Released Ge also markedly inhibited EGFR signaling. This combined EGFR-targeted action achieved remarkable anti-glioma effects and could be a safe and effective treatment for glioma. KEY MESSAGES: Angiopep-2-modified cationic lipid polymer can penetrate the BBB. Gefitinib can inhibit EGFR signaling and block the autophosphorylation of critical tyrosine residues on EGFR. GOLPH3 siRNA can be transfected into glioma and downregulate GLOPH3 expression. A2-N/Ge/siGOLPH3 can inhibit glioma growth.
AuthorsChengkun Ye, Bomin Pan, Haoyue Xu, Zongren Zhao, Jiawei Shen, Jun Lu, Rutong Yu, Hongmei Liu
JournalJournal of molecular medicine (Berlin, Germany) (J Mol Med (Berl)) Vol. 97 Issue 11 Pg. 1575-1588 (11 2019) ISSN: 1432-1440 [Electronic] Germany
PMID31673738 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • GOLPH3 protein, human
  • GPP34 protein, mouse
  • Membrane Proteins
  • Phosphoproteins
  • RNA, Small Interfering
  • EGFR protein, human
  • ErbB Receptors
  • Gefitinib
Topics
  • Animals
  • Cell Proliferation (genetics, physiology)
  • ErbB Receptors (genetics, metabolism)
  • Gefitinib (therapeutic use)
  • Gene Expression Regulation, Neoplastic (genetics, physiology)
  • Glioma (drug therapy, metabolism)
  • Humans
  • Male
  • Membrane Proteins (genetics, metabolism)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Nanoparticles (chemistry)
  • Phosphoproteins (genetics, metabolism)
  • RNA, Small Interfering (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: